Research has shown a higher rate of death from COVID-19 in people with schizophrenia and schizoaffective disorder, but the cause is not known. To investigate a possible cause, researchers analyzed data on more than 400 individuals with serious mental illness who had been diagnosed with COVID-19. Although the findings confirmed increased risk of mortality among patients with schizophrenia spectrum disorders, the study found no increased risk in those taking antipsychotic medication. Further research is needed to understand this issue, but this study supports the safety of maintaining an antipsychotic regimen while at risk for COVID-19. To learn more, see the study in JAMA.